Humana (NYSE:HUM) Posts Quarterly Earnings Results, Beats Estimates By $1.51 EPS

Humana (NYSE:HUM - Get Free Report) announced its quarterly earnings results on Wednesday. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.07 by $1.51, Zacks reports. The firm had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $7.23 earnings per share.

Humana Stock Down 2.3 %

HUM stock opened at $256.11 on Friday. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $30.91 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 2.05 and a beta of 0.62. The business's fifty day moving average price is $266.20 and its two-hundred day moving average price is $270.62.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.38%. Humana's dividend payout ratio (DPR) is presently 35.58%.

Hedge Funds Weigh In On Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 798 shares of the insurance provider's stock, valued at approximately $202,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on HUM shares. Robert W. Baird upped their price target on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Truist Financial lifted their price objective on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research note on Friday, April 11th. Guggenheim started coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research report on Thursday. Finally, Morgan Stanley reduced their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $287.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.